Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations
- 3 April 2017
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (6) , 702-711
Abstract
The aim of this study was to examine the association between optimal adherence to first-line disease-modifying therapies (DMT) for multiple sclerosis (MS) and hospitalizations. We used population-based administrative data from three Canadian provinces. All individuals receiving DMT (interferon-B-1b, interferon-B-1a, or glatiramer acetate) between January 1, 1996, and December 31, 2011 (British Columbia); March 31, 2012 (Manitoba); or March 31, 2014, (Saskatchewan) were included. Adherence was estimated for the first year of DMT (year 0), using the medication possession ratio (MPR). The association between optimal adherence (MPR ≥ 80%) and all-cause and MS-specific hospitalizations in the subsequent 1, 2, and 5 years was assessed using Hurdle Poisson and logistic regression. Rate and odds ratios were adjusted (aRR and aOR) for sociodemographic factors and prior health-care utilization. Overall, 4746 subjects were followed for a mean 7.8 (SD 4.0) years; 3598 (76%) were women. Optimal DMT adherence was achieved in 3564/4746 (75.1%) subjects. Subsequent all-cause and MS-specific hospitalizations were lower for subjects with optimal versus suboptimal adherence, but none reached statistical significance (1-year period, aRR = 0.77, 95%CI: 0.47–1.26; aOR = 0.80, 95%CI: 0.52–1.25). Similar findings were observed in the 2-year and 5-year periods. Prior health-care utilization (hospitalizations and medications) was associated with future hospitalizations; for every additional medication class, the 5-year all-cause hospitalization rate and likelihood of an MS-specific hospitalization increased by 5% and 11%, respectively (aRR = 1.05, 95%CI: 1.02–1.07; and aOR = 1.11, 95%CI: 1.07–1.14). Hospitalization rates were lower in subjects with optimal DMT adherence, but findings were not statistically significant. Prior hospitalization and polypharmacy were associated with increased risk for future hospitalizations in MS. Copyright © 2017 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Multiple Sclerosis Society (RG-4757-A-3)
This publication has 43 references indexed in Scilit:
- Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid useJournal of Neurology, 2013
- Participation in a Clinical Trial Enhances Adherence and Persistence to TreatmentHypertension, 2011
- Zero-Inflated and Hurdle Models of Count Data with Extra Zeros: Examples from an HIV-Risk Reduction Intervention TrialThe American Journal of Drug and Alcohol Abuse, 2011
- The rising prevalence and changing age distribution of multiple sclerosis in ManitobaNeurology, 2010
- Impact of Adherence to Interferons in the Treatment of Multiple SclerosisClinical Drug Investigation, 2010
- Statin Adherence and Risk of AccidentsCirculation, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Case finding for patients at risk of readmission to hospital: development of algorithm to identify high risk patientsBMJ, 2006
- A meta-analysis of the association between adherence to drug therapy and mortalityBMJ, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005